Adc Therapeutics Sa (ADCT) fundamentals score
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through its focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.
Pharmaceutical Preparations · Healthcare · Listed on NYSE
Overall: 4.2 out of 10, Weak long-term fundamentals
- Growth: 3.3/10
- Profitability: 4.0/10
- Financial health: 4.4/10
- Earnings quality: 6.1/10
- Valuation: 4.0/10
Scores are calculated from Adc Therapeutics Sa’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10